[go: up one dir, main page]

AU1208892A - Immunotoxin from anti-cd5 monoclonal antibodies - Google Patents

Immunotoxin from anti-cd5 monoclonal antibodies

Info

Publication number
AU1208892A
AU1208892A AU12088/92A AU1208892A AU1208892A AU 1208892 A AU1208892 A AU 1208892A AU 12088/92 A AU12088/92 A AU 12088/92A AU 1208892 A AU1208892 A AU 1208892A AU 1208892 A AU1208892 A AU 1208892A
Authority
AU
Australia
Prior art keywords
immunotoxin
monoclonal antibodies
monoclonal
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12088/92A
Other languages
English (en)
Inventor
Gianni Gromo
Daniela Modena
Giuliana Porro
Fiorenzo Stirpe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of AU1208892A publication Critical patent/AU1208892A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6825Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU12088/92A 1991-02-26 1992-02-18 Immunotoxin from anti-cd5 monoclonal antibodies Abandoned AU1208892A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI91A000491 1991-02-26
ITMI910491A IT1249051B (it) 1991-02-26 1991-02-26 Immunotossina da anticorpi monoclonali anti-cd5

Publications (1)

Publication Number Publication Date
AU1208892A true AU1208892A (en) 1992-09-15

Family

ID=11358745

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12088/92A Abandoned AU1208892A (en) 1991-02-26 1992-02-18 Immunotoxin from anti-cd5 monoclonal antibodies

Country Status (4)

Country Link
EP (1) EP0577612A1 (it)
AU (1) AU1208892A (it)
IT (1) IT1249051B (it)
WO (1) WO1992014491A1 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
CA3082310A1 (en) 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd5+ cells
BR112021021165A2 (pt) 2019-04-24 2022-01-04 Heidelberg Pharma Res Gmbh Conjugados anticorpo-fármaco de amatoxina e uso dos mesmos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363799A (en) * 1979-03-20 1982-12-14 Ortho Pharmaceutical Corporation Monoclonal antibody to human T cells, and methods for preparing same
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
DE3581210D1 (de) * 1985-03-04 1991-02-07 Dana Farber Cancer Inst Inc Immunotoxin und herstellung.
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
AU633251B2 (en) * 1988-02-03 1993-01-28 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
JPH03503164A (ja) * 1988-02-03 1991-07-18 エクソウマ コーポレーション 抗‐パンt‐細胞イムノトキシン組成物による免疫抑制
WO1989011871A1 (en) * 1988-06-01 1989-12-14 Cetus Corporation One-step chromatographic purification of immunotoxin conjugates using a thiophilic matrix

Also Published As

Publication number Publication date
IT1249051B (it) 1995-02-11
ITMI910491A1 (it) 1992-08-26
WO1992014491A1 (en) 1992-09-03
ITMI910491A0 (it) 1991-02-26
EP0577612A1 (en) 1994-01-12

Similar Documents

Publication Publication Date Title
AU4042195A (en) Anti-alphaV-integrin monoclonal antibody
AU4618193A (en) Humanized antibodies
IL99363A0 (en) Pharmaceutical compositions comprising homoconjugated monoclonal antibodies
AU4025193A (en) Humanized C-erbB-2 specific antibodies
PL309249A1 (en) Humanised antibodies against l-selectin
AU7411896A (en) Bispecific antibody heterodimers
AU1289795A (en) Monoclonal antibodies specific for human interleukin-5
AU5283893A (en) Recombinant humanized anti-cytomegalovirus antibodies
AU6080794A (en) Antibodies directed against binding-associated epitopes
EP0578515A3 (en) Humanized monoclonal antibodies.
EP0580859A4 (en) Anti-eda monoclonal antibody
GB9412166D0 (en) Retargetting antibodies
EP0683675A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS.
EP0506523A3 (en) Monoclonal antibodies
AU1025692A (en) Novel chimeric antiidiotypic monoclonal antibodies
AU1208892A (en) Immunotoxin from anti-cd5 monoclonal antibodies
EP0562125A4 (en) Antibody composition.
AU4195793A (en) Bispecific antibody
AU8547291A (en) Monoclonal antibodies against tenascin
AU1809695A (en) Tumor associated monoclonal antibody 123av16
EP0508282A3 (en) Anti-idiotypic monoclonal antibodies
EP0654532A4 (en) ANTIMUCOGLYCOPROTEIN MONOCLONAL ANTIBODIES.
AU3008892A (en) Tumor associated monoclonal antibody 88bv59
AU7862291A (en) Modified antibodies
EP0671924A4 (en) DIGITALIN LIKE COMPOUNDS.